Trial Shows Tirzepatide May Benefit People with Obesity, Kidney Disease and Heart Failure
Advertisement
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to study published in Journal of the American College of Cardiology. The overall rate of cardiovascular death or worsening heart failure, the trial’s primary endpoint, was higher in the 60% of study participants who also had chronic kidney disease. However, tirzepatide reduced the risk of the primary endpoint to a similar degree in patients with and without kidney disease.
In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have interacting root causes and are associated with poor outcomes, indicating a significant unmet need.
The SUMMIT trial enrolled 731 patients with heart failure with preserved ejection fraction and a body mass index of 30 m2/kg or higher. About 60% of the study participants also had chronic kidney disease. Half were randomly assigned to receive tirzepatide and half received a placebo. Neither patients nor their clinicians were aware of which regimen they had been assigned.
At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure compared with the placebo group.
The researchers used two strategies for assessing kidney function, measuring creatinine and cystatin C at 12, 24 and 52 weeks. Ultimately, participants taking tirzepatide showed significant improvements over those taking placebo in terms of both markers of kidney function, although the results showed different patterns over time and among different patient groups.
Reference: Packer, M, Zile, M, Kramer, C. et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. JACC. null2025, 0 (0). https://doi.org/10.1016/j.jacc.2025.03.009
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.